← All indications
Digestive System Diseases
Diseases in any part of the GASTROINTESTINAL TRACT or the accessory organs (LIVER; BILIARY TRACT; PANCREAS).
Subtype terms (8)
More specific conditions that are subtypes of Digestive System Diseases in the MeSH hierarchy.
- Biliary Tract Diseases
20 drugs (15 approved, 5 experimental)
- Digestive System Abnormalities
- Digestive System Fistula
1 drug approved
- Digestive System Neoplasms
87 drugs (39 approved, 48 experimental)
- Gastrointestinal Diseases
152 drugs (66 approved, 86 experimental)
- Liver Diseases
572 drugs (303 approved, 269 experimental)
- Pancreatic Diseases
53 drugs (36 approved, 17 experimental)
- Peritoneal Diseases
1 drug approved
Drugs by status
Approved for this indication (1)
Phase 4 trials (13)
Phase 3 trials (19)
Phase 2 trials (28)
- anlotinib
- anti-interferon-gamma monoclonal antibody
- berberine
- burlulipase
- irinotecan
- da jian zhong tang
- khk4083
- ursodeoxycholic acid
- ribavirin
- alectinib
- semaglutide
- pentoxifylline
- uprifosbuvir
- capecitabine
- nexvax2
- esophageal cancer peptide specific ctl
- gimeracil
- oteracil
- oxaliplatin
- cisplatin
- tegafur
- oncoxin-viusid
- camrelizumab
- Lactobacillus acidophilus
- monoammonium glycyrrinate
- penpulimab
- the-630
- tqb2450
Phase 1 trials (12)
Other trials (31)
- maltodextrin
- aquamin
- bifidobacterium animalis
- cranberry
- pancrelipase
- calcium
- lactulose
- magnesium oxide
- whey protein
- mupirocin
- orange juice
- cow milk
- caffeine
- rifaximin
- vancomycin
- apple
- gluten
- oat
- prebiotic fiber
- bacillus subtilis
- domperidone
- droperidol
- dobutamine
- omeprazole
- propionibacterium freudenreichii
- lactobacillus reuteri
- orange pomace
- acetobacter
- bc006
- fermented dairy protein
- +1 more
Organizations
Organization Involved with Phase 4 Indications (27)
- Sanofi
- Novartis
- Harrison Clinical Research
- Laboratorios Ordesa
- Norgine
- Shenzhen Kangtai Biological Products Co., LTD
- Alexandra Hospital, Athens, Greece
- Cedars-Sinai Medical Center
- China Academy of Chinese Medical Sciences
- Medical University of Warsaw
- Northwestern University
- Universidad Autonoma de Madrid
- Ufuk University
- University of Oslo
- St. Louis University
- University of California, Los Angeles
- University of Naples Frederico II
- Jiao Tong University
- Hospital Joan XXIII de Tarragona, Tarragona, Spain
- Rovira i Virgili University
- Government of China
- Washington University in St. Louis
- CHU Edouard Herriot
- International Clinical Trials Association
- American College of Gastroenterology
- Government of Norway
- Hellenic Society of Gastroenterology
Organization Involved with Phase 3 Indications (31)
- Abbott
- Takeda
- Celgene
- AstraZeneca
- Astra
- Ipsen
- Bellus Health Inc
- Laboratorio Saude Ltda.
- Valio Ltd
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Cancer Research Network
- Chang Gung University
- Harvard University
- Federal University of Rio Grande do Sul
- Nanjing University
- Chinese University of Hong Kong
- University of Cincinnati
- Food and Drug Administration
- The University of Hong Kong
- University of Texas at Houston
- University of Nantes
- National Center for Advancing Translational Science (NCATS)
- Government of Finland
- Finnish Defense Forces
- Pharmbio Korea
- New Bellus Enterprises
- University of Helsinki
- +1 more
Organization Involved with Phase 2 Indications (48)
- Facet Biotech
- Ironwood Pharmaceuticals
- Bausch Health Companies
- Roche
- Cato Research
- Merck
- Sanofi-Synthelabo
- Bayer
- Catalysis SL
- Danisco
- Hengrui Therapeutics, Inc.
- HighTide Biopharma Pty Ltd
- ImmusanT, Inc.
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- Kyowa Hakko Kirin
- Nordmark Arzneimittel GmbH & Co. KG
- Parexel
- PediaMed Pharmaceuticals
- S-Evans Biosciences Co.,Ltd.
- Shenzhen Hornetcorn Bio-technology Company, LTD
- Boehringer Ingelheim
- Ethicon
- National Center for Research Resources (NCRR)
- Hangzhou Cancer Hospital
- Arizona State University
- Guangzhou Medical University
- Hong Kong Baptist University
- Johns Hopkins University
- Singapore General Hospital
- The Canadian College of Naturopathic Medicine
- +18 more
Organization Involved with Phase 1 Indications (18)
- Novo Nordisk
- Genentech
- Blueprint Medicines Corporation
- Menarini Group
- Maastricht University
- Case Western Reserve University
- Inje University
- University of Groningen
- University of Michigan
- Uppsala University
- CJ HealthCare Corp.
- Free University of Amsterdam
- Conatus Pharmaceuticals
- Karolinska Institute
- Anaheim Clinical Trials
- Top Institute Food and Nutrition
- Children's Hospital Los Angeles
- PvP Biologics, Inc.
Organization Involved with Other Experimental Indications (45)
- Digestive Care, Inc.
- Lesaffre International
- Marigot Ltd.
- Palo Alto Medical Foundation
- ZonMw: The Netherlands Organisation for Health Research and Development
- Children's Hospital of Philadelphia
- Aarhus University
- University of Pennsylvania
- Carle Foundation Hospital
- Carle Physician Group
- University of London
- George Mason University
- Hospital Beatriz Ângelo
- Jiangxi University of Traditional Chinese Medicine
- Norwegian University of Science and Technology
- Ohio State University
- Radboud University
- Stanford University
- Sykehuset Innlandet HF
- University Hospital of North Norway
- University of Nottingham
- Utrecht University
- University of Alberta
- University of Bari
- University of Bern
- Zagazig University
- Bogomolets National Medical University
- Colorado State University
- Fudan University
- Nanchang University
- +15 more